Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis

por Brown, JWL, Coles, Alasdair J
Publicado 2013

Case reports in the Lancet: From neurophobia to global pandemics

por Devoy, Benjamin O., Bennett, Peter J., Coles, Alasdair J., Mousa, Hani S.
Publicado 2022

Neurological Implications of COVID-19 Infections

por Needham, Edward J., Chou, Sherry H.-Y., Coles, Alasdair J., Menon, David K.
Publicado 2020

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients

por Georgieva, Zoya G, Dӧffinger, Rainer, Kumararatne, Dinakantha, Coles, Alasdair J, McCarthy, Claire
Publicado 2021

Disease-relevant autoantibodies in first episode schizophrenia

por Zandi, Michael S., Irani, Sarosh R., Lang, Bethan, Waters, Patrick, Jones, Peter B., McKenna, Peter, Coles, Alasdair J., Vincent, Angela, Lennox, Belinda R.
Publicado 2010

Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependent

por McMurran, Christopher E., Mukherjee, Trisha, Brown, J William L., Michell, Andrew W., Chard, Declan T., Franklin, Robin J. M., Coles, Alasdair J., Cunniffe, Nick G.
Publicado 2022

Hyperpolarized (13)C MRI: A novel approach for probing cerebral metabolism in health and neurological disease

por Grist, James T, Miller, Jack J, Zaccagna, Fulvio, McLean, Mary A, Riemer, Frank, Matys, Tomasz, Tyler, Damian J, Laustsen, Christoffer, Coles, Alasdair J, Gallagher, Ferdia A
Publicado 2020

Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation

por Khandaker, Golam M, Oltean, Bianca P, Kaser, Muzaffer, Dibben, Claire R M, Ramana, Rajini, Jadon, Deepak R, Dantzer, Robert, Coles, Alasdair J, Lewis, Glyn, Jones, Peter B
Publicado 2018

The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro

por Gaunt, Christopher M., Rainbow, Daniel B., Mackenzie, Ruairi J., Jarvis, Lorna B., Mousa, Hani S., Cunniffe, Nicholas, Georgieva, Zoya, Brown, J. William, Coles, Alasdair J., Jones, Joanne L.
Publicado 2021

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

por Phelps, Richard, Winston, Jonathan A, Wynn, Daniel, Habek, Mario, Hartung, Hans-Peter, Havrdová, Eva Kubala, Markowitz, Glen S, Margolin, David H, Rodriguez, Claudio E, Baker, Darren P, Coles, Alasdair J
Publicado 2019

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

por Giovannoni, Gavin, Cohen, Jeffrey A., Coles, Alasdair J., Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Margolin, David H., Lake, Stephen L., Kaup, Susan M., Panzara, Michael A., Compston, D. Alastair S.
Publicado 2016

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

por Coles, Alasdair J., Achiron, Anat, Traboulsee, Anthony, Singer, Barry A., Pozzilli, Carlo, Oreja-Guevara, Celia, Giovannoni, Gavin, Comi, Giancarlo, Freedman, Mark S., Ziemssen, Tjalf, Shiota, Debora, Rawlings, Andreea M., Wong, Alana T., Chirieac, Magdalena, Montalban, Xavier
Publicado 2023

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

por Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S
Publicado 2018

Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes

por Zandi, Michael S, Paterson, Ross W, Ellul, Mark A, Jacobson, Leslie, Al-Diwani, Adam, Jones, Joanne L, Cox, Amanda L, Lennox, Belinda, Stamelou, Maria, Bhatia, Kailash P, Schott, Jonathan M, Coles, Alasdair J, Kullmann, Dimitri M, Vincent, Angela
Publicado 2014

Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from (23)Na-MRI

por Grist, James T., Riemer, Frank, McLean, Mary A., Matys, Tomasz, Zaccagna, Fulvio, Hilborne, Sarah F., Mason, Jackie P., Patterson, Ilse, Slough, Rhys, Kaggie, Joshua, Deen, Surrin S., Graves, Martin J., Jones, Joanne L., Coles, Alasdair J., Gallagher, Ferdia A.
Publicado 2018

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

por Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Publicado 2021

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

por Coles, Alasdair J, Jones, Joanne L, Vermersch, Patrick, Traboulsee, Anthony, Bass, Ann D, Boster, Aaron, Chan, Andrew, Comi, Giancarlo, Fernández, Óscar, Giovannoni, Gavin, Kubala Havrdova, Eva, LaGanke, Christopher, Montalban, Xavier, Oreja-Guevara, Celia, Piehl, Fredrik, Wiendl, Heinz, Ziemssen, Tjalf
Publicado 2021

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

por Arnold, Douglas L., Fisher, Elizabeth, Brinar, Vesna V., Cohen, Jeffrey A., Coles, Alasdair J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Stojanovic, Miroslav, Weiner, Howard L., Lake, Stephen L., Margolin, David H., Thomas, David R., Panzara, Michael A., Compston, D. Alastair S.
Publicado 2016

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

por Coles, Alasdair J., Cohen, Jeffrey A., Fox, Edward J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Chirieac, Madalina C., Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J., Panzara, Michael A., Arnold, Douglas L.
Publicado 2017

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

por Havrdova, Eva, Arnold, Douglas L., Cohen, Jeffrey A., Hartung, Hans-Peter, Fox, Edward J., Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Jody, Darlene, Hogan, Richard J., Xenopoulos, Panos, Panzara, Michael A., Coles, Alasdair J.
Publicado 2017